Journal Article > ReviewFull Text
Arch Bronconeumol. 1 July 2020; Volume 56 (Issue 7); 446-454.; DOI:10.1016/j.arbres.2019.11.015
Letang E, Ellis J, Naidoo K, Casas EDT, Sanchez P, et al.
Arch Bronconeumol. 1 July 2020; Volume 56 (Issue 7); 446-454.; DOI:10.1016/j.arbres.2019.11.015
Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.